Press coverage about Nightstar Therapeutics (NASDAQ:NITE) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nightstar Therapeutics earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.903850392916 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Nightstar Therapeutics (NASDAQ:NITE) traded up $0.30 during trading on Wednesday, hitting $14.61. 27,100 shares of the stock traded hands, compared to its average volume of 31,250. Nightstar Therapeutics has a twelve month low of $11.99 and a twelve month high of $24.93.

NITE has been the subject of several analyst reports. BMO Capital Markets initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $30.00 price target for the company. Jefferies Group initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 price target for the company. Wedbush initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $19.00 price target for the company. Leerink Swann initiated coverage on shares of Nightstar Therapeutics in a research note on Monday, October 23rd. They issued an “outperform” rating and a $25.00 price target for the company. Finally, Chardan Capital initiated coverage on shares of Nightstar Therapeutics in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 price target for the company. Five investment analysts have rated the stock with a buy rating, Nightstar Therapeutics has an average rating of “Buy” and an average target price of $30.20.

COPYRIGHT VIOLATION WARNING: “Nightstar Therapeutics (NITE) Given Daily Coverage Optimism Rating of 0.08” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/nightstar-therapeutics-nite-given-daily-coverage-optimism-rating-of-0-08/1810923.html.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Insider Buying and Selling by Quarter for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.